On June 12, Ascentage Pharma rose 5.42% in regular trading, reaching HK$35.28/share with turnover of HK$52.76 million, rebounding from a 52-week low of HK$32.50 touched earlier in the week.

The rally comes amid a broad biotech sector recovery and multiple company-specific catalysts. On June 10 and 11, the company's trustee purchased a combined 300,000 shares on-market for the 2022 Restricted Share Unit Plan, signaling management confidence. Additionally, Ascentage's ASCO 2026 presentations continue to draw attention, including oral abstract-level data on its APG-115 combined with lisaftoclax (APG-2575) in pediatric solid tumors — the first clinical validation globally of the MDM2-p53 plus BCL-2 dual apoptosis pathway.

Within the Biotechnology sector, multiple peers posted gains: AKESO up 7.0%, SKB BIO up 8.77%, INNOVENT BIO up 4.59%, 3SBIO up 3.88%, and BEIGENE up 1.87%, reflecting sector-wide recovery following the post-ASCO pullback.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)